Exogenous Therapeutics of Microrna-29a Attenuates Development of Hepatic Fibrosis in Cholestatic Animal Model Through Regulation of Phosphoinositide 3-Kinase P85 Alpha

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 May 28

PMID 32455716

Citations 12

Authors

Ya-Ling Yang

Feng-Sheng Wang

Hung-Yu Lin

Ying-Hsien Huang

Affiliations

Soon will be listed here.

Abstract

Recent studies have found that microRNA-29a (miR-29a) levels are significantly lower in fibrotic livers, as shown with human liver cirrhosis. Such downregulation influences the activation of hepatic stellate cells (HSC). Phosphoinositide 3-kinase p85 alpha (PI3KP85α) is implicated in the regulation of proteostasis mitochondrial integrity and unfolded protein response (UPR) and apoptosis in hepatocytes. This study aimed to investigate the potential therapeutic role of miR-29a in a murine bile duct ligation (BDL)-cholestatic injury and liver fibrosis model. Mice were assigned to four groups: sham, BDL, BDL + scramble miRs, and BDL + miR-29a-mimic. Liver fibrosis and inflammation were assessed by histological staining and mRNA/protein expression of representative markers. Exogenous therapeutics of miR-29a in BDL-stressed mice significantly attenuated glutamic oxaloacetic transaminase (GOT)/glutamic-pyruvic transaminase (GPT) and liver fibrosis, and caused a significant downregulation in markers related to inflammation (IL-1β), fibrogenesis (TGF-β1, α-SMA, and COL1α1), autophagy (p62 and LC3B II), mitochondrial unfolded protein response (UPR; C/EBP homologous protein (CHOP), heat shock protein 60 (HSP60), and Lon protease-1 (LONP1, a mitochondrial protease), and PI3KP85α within the liver tissue. An in vitro luciferase reporter assay further confirmed that miR-29a mimic directly targets mRNA 3' untranslated region (UTR) of PI3KP85α to suppress its expression in HepG2 cell line. Our data provide new insights that therapeutic miR-29a improves cholestasis-induced hepatic inflammation and fibrosis and proteotstasis via blocking PI3KP85α, highlighting the potential of miR-29a targeted therapy for liver injury.

Citing Articles

Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.

Zhao J, Yue P, Mi N, Li M, Fu W, Zhang X Med Rev (2021). 2024; 4(4):326-365.

PMID: 39135601 PMC: 11317084. DOI: 10.1515/mr-2024-0029.

MicroRNA-29a Mitigates Laminectomy-Induced Spinal Epidural Fibrosis and Gait Dysregulation by Repressing TGF-β1 and IL-6.

Lin I, Lin Y, Lian W, Wang F, Wu R Int J Mol Sci. 2023; 24(11).

PMID: 37298111 PMC: 10252628. DOI: 10.3390/ijms24119158.

Dihydroartemisinin inhibits the activation and proliferation of hepatic stellate cells by regulating miR‑29b‑3p.

Huan S, Sun S, Song S, Dai J, Zhu G, Zhong Y Int J Mol Med. 2023; 51(5).

PMID: 37026504 PMC: 10094948. DOI: 10.3892/ijmm.2023.5243.

Role of noncoding RNAs in liver fibrosis.

Li Q, Gong T, Huang Y, Kang L, Warner C, Xie H World J Gastroenterol. 2023; 29(9):1446-1459.

PMID: 36998425 PMC: 10044853. DOI: 10.3748/wjg.v29.i9.1446.

Potential role of microRNAs in selective hepatic insulin resistance: From paradox to the paradigm.

Palihaderu P, Mendis B, Premarathne J, Dias W, Yeap S, Ho W Front Endocrinol (Lausanne). 2022; 13:1028846.

PMID: 36479211 PMC: 9720316. DOI: 10.3389/fendo.2022.1028846.

References

Liu W, Jing Z, Xue C, Wu S, Chen W, Lin X . PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019; 381:114729. DOI: 10.1016/j.taap.2019.114729. View

Roderburg C, Urban G, Bettermann K, Vucur M, Zimmermann H, Schmidt S . Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2010; 53(1):209-18. DOI: 10.1002/hep.23922. View

Jackson A, Linsley P . Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010; 9(1):57-67. DOI: 10.1038/nrd3010. View

Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos M, Pardo V, Miquilena-Colina M . Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014; 5:e1179. PMC: 4001315. DOI: 10.1038/cddis.2014.162. View

Friedman S . Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008; 88(1):125-72. PMC: 2888531. DOI: 10.1152/physrev.00013.2007. View

Duan M, Yang Y, Peng S, Liu X, Zhong J, Guo Y . C/EBP Homologous Protein (CHOP) Activates Macrophages and Promotes Liver Fibrosis in -Infected Mice. J Immunol Res. 2019; 2019:5148575. PMC: 6914929. DOI: 10.1155/2019/5148575. View

Senft D, Ronai Z . UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci. 2015; 40(3):141-8. PMC: 4340752. DOI: 10.1016/j.tibs.2015.01.002. View

Son M, Ryu Y, Jung K, Lee H, Lee H, Yan H . HS-173, a novel PI3K inhibitor, attenuates the activation of hepatic stellate cells in liver fibrosis. Sci Rep. 2013; 3:3470. PMC: 3858860. DOI: 10.1038/srep03470. View

Liu R, Li X, Huang Z, Zhao D, Ganesh B, Lai G . C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology. 2017; 67(4):1441-1457. PMC: 5859257. DOI: 10.1002/hep.29540. View

10.

Huang J, Yu X, Fries J, Zhang L, Odenthal M . MicroRNA function in the profibrogenic interplay upon chronic liver disease. Int J Mol Sci. 2014; 15(6):9360-71. PMC: 4100099. DOI: 10.3390/ijms15069360. View

11.

Chen X, Bian M, Zhang C, Kai J, Yao Z, Jin H . Dihydroartemisinin inhibits ER stress-mediated mitochondrial pathway to attenuate hepatocyte lipoapoptosis via blocking the activation of the PI3K/Akt pathway. Biomed Pharmacother. 2017; 97:975-984. DOI: 10.1016/j.biopha.2017.11.010. View

12.

Shpilka T, Haynes C . The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. Nat Rev Mol Cell Biol. 2017; 19(2):109-120. DOI: 10.1038/nrm.2017.110. View

13.

Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y . MiR-29a Assists in Preventing the Activation of Human Stellate Cells and Promotes Recovery From Liver Fibrosis in Mice. Mol Ther. 2016; 24(10):1848-1859. PMC: 5112039. DOI: 10.1038/mt.2016.127. View

14.

Huang Y, Yang Y, Wang F . The Role of miR-29a in the Regulation, Function, and Signaling of Liver Fibrosis. Int J Mol Sci. 2018; 19(7). PMC: 6073598. DOI: 10.3390/ijms19071889. View

15.

Chu Q, Martinez T, Novak S, Donaldson C, Tan D, Vaughan J . Regulation of the ER stress response by a mitochondrial microprotein. Nat Commun. 2019; 10(1):4883. PMC: 6814811. DOI: 10.1038/s41467-019-12816-z. View

16.

Huang Y, Kuo H, Yang Y, Wang F . MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. Int J Med Sci. 2019; 16(2):212-220. PMC: 6367521. DOI: 10.7150/ijms.29930. View

17.

Huang Y, Yang Y, Huang F, Tiao M, Lin Y, Tsai M . MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. Exp Biol Med (Maywood). 2017; 243(1):13-21. PMC: 5788159. DOI: 10.1177/1535370217741500. View

18.

Yi H . Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases. Endocrinol Metab (Seoul). 2019; 34(1):39-46. PMC: 6435852. DOI: 10.3803/EnM.2019.34.1.39. View

19.

Bandyopadhyay S, Friedman R, Marquez R, Keck K, Kong B, Icardi M . Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis. 2011; 203(12):1753-62. PMC: 3143452. DOI: 10.1093/infdis/jir186. View

20.

Li S, Wang F, Yang Y, Tiao M, Chuang J, Huang Y . Microarray Study of Pathway Analysis Expression Profile Associated with MicroRNA-29a with Regard to Murine Cholestatic Liver Injuries. Int J Mol Sci. 2016; 17(3):324. PMC: 4813186. DOI: 10.3390/ijms17030324. View